Dr. Melody A. Cobleigh, MD

Dr. Cobleigh practices at Rush University Medical Center in Chicago, Illinois, part of Rush System for Health.

Dr. Cobleigh's NPI, 1861451122, was assigned on March 23, 2006. Dr. Cobleigh graduated from Rush Medical College of Rush University in 1976. Dr. Cobleigh holds Illinois license 036-054142.

Dr. Cobleigh's primary practice is Rush University Medical Center, at 1653 West Congress Parkway, Chicago, IL 60612 in Cook County. The practice phone is (312) 942-5000.

Dr. Cobleigh's primary practice is Rush University Medical Center in Chicago, Illinois, part of Rush System for Health. Dr. Cobleigh is also affiliated with Rush Oak Park Hospital. The medical group on file is Rush University Internists. Dmand AI also links Dr. Cobleigh to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cobleigh practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Cobleigh's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Cobleigh is licensed in Illinois.

Dmand AI lists breast cancer and multiple myeloma among the conditions Dr. Cobleigh treats.

CMS data shows 377 Medicare services from Dr. Cobleigh across 3 procedure codes in 2024, for 86 Medicare patients. Medicare paid $34,064 for them.

CMS counts 86 Medicare patients who saw Dr. Cobleigh in 2024. The largest group is 65 to 74, with 46 patients. 75% of them have cancer, and 74% have high cholesterol. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cobleigh's median patient age at 71, with 98% women.

In 2024, Dr. Cobleigh wrote 382 Medicare Part D claims for 77 patients. 65% of them were for generic drugs. CMS names the drug for 287 of them, across 9 drugs with 11 or more claims each, at $1,695,813 in total drug cost. In 2023, CMS named 221 claims across 9 drugs.

Dr. Cobleigh accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 78 papers to Dr. Cobleigh, published from 2003 to 2024. 2019 was the busiest year, with 8. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Neoplasm Metastasis. Dr. Cobleigh has published most often in J Clin Oncol. Dr. Cobleigh's most frequent co-authors are Lydia Usha, MD, Hope S. Rugo, MD and Eleftherios P. Mamounas, MD.

Dmand AI links Dr. Cobleigh to 10 clinical trials, 6 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Breast Carcinoma In Situ, Breast Neoplasms and Breast Neoplasms, Male. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 57 general payments to Dr. Cobleigh from 6 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 58% of the total. Genentech, Inc. paid the most, $31,803. It also lists 1 research payment totaling $824 in 2021.

Dmand AI lists 7 awards for Dr. Cobleigh, most recently America's Top Doctors in 2017.

Dr. Cobleigh graduated from Rush Medical College of Rush University in 1976.

Dr. Cobleigh is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.